Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.